Home Cart Sign in  
Chemical Structure| 124753-97-5 Chemical Structure| 124753-97-5

Structure of C6 Ceramide
CAS No.: 124753-97-5

Chemical Structure| 124753-97-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

C6 Ceramide is an activator of the ceramide pathway, showing activity against various cancer cell lines and serving as an adjuvant to enhance the anticancer effects of chemotherapeutic agents.

Synonyms: C6-Cer; N-Hexanoylsphingosine; N-C6:0-D-erythro-Ceramide

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of C6 Ceramide

CAS No. :124753-97-5
Formula : C24H47NO3
M.W : 397.63
SMILES Code : CCCCCCCCCCCCC/C=C/[C@H]([C@H](CO)NC(CCCCC)=O)O
Synonyms :
C6-Cer; N-Hexanoylsphingosine; N-C6:0-D-erythro-Ceramide
MDL No. :MFCD00870174

Safety of C6 Ceramide

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
MCF-7 cells 50 μM 24 h Induced MCF-7 cell death via autophagy Int J Biol Sci. 2011;7(5):629-44
HT-29 cells 5 μM 72 h Facilitated ABC294640-induced cytotoxicity against HT-29 cells J Exp Clin Cancer Res. 2015 Sep 4;34(1):94.
NCI/ADR-RES cells 25 μM 48 hr C6-ceramide substantially increased the levels of phosphorylated p53 and enhanced the expression of p53-responsive genes such as p21Waf1/Cip1, Bax, and Puma. Cancer Res. 2011 Mar 15;71(6):2276-85
p56lck-reconstituted JCaM1.6 cells 10 μM 15-25 min Reconstitution of p56lck partially restored the inhibitory effect of C6-ceramide on n-K1 channels. Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7661-6
p56lck-deficient JCaM1.6 cells 10 μM 20 min In p56lck-deficient cells, the inhibitory effect of C6-ceramide on n-K1 channels was significantly reduced. Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7661-6
Jurkat T lymphocytes 10 μM 15-25 min C6-ceramide significantly inhibited n-K1 channel currents, with a 41±5% decrease at 15 min and 67±6% decrease at 25 min. Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7661-6
Human adipose derived stem cells (hADSC) 20 µM 48 h C6-ceramide increased cellular and exosomal MALAT1 levels and promoted migration and mitochondrial function in human dermal fibroblasts. Cell Commun Signal. 2023 Aug 24;21(1):221
Bone marrow-derived macrophages (BMMs) 25 µM 24 h LipC6 significantly inhibited ROS production in both GMCSF-induced M1 BMMs and MCSF-induced M2 BMMs, promoted M1 cytokine production, and suppressed M2 cytokine production. Gastroenterology. 2018 Mar;154(4):1024-1036. e9
HEK293 cells 40 μM 24 h To evaluate the effect of CNL on non-transformed cells. CNL treatment did not affect the viability of HEK293 cells or STAT3 phosphorylation. Signal Transduct Target Ther. 2017 Oct 27;2:17051
Mec-2 cells 40 μM 24 h To evaluate the effect of CNL on STAT3 phosphorylation. A reduction in STAT3 phosphorylation at Y705 and S727 residues was observed. Signal Transduct Target Ther. 2017 Oct 27;2:17051
JVM-3 cells 40 μM 24 h To evaluate the effect of CNL on STAT3 phosphorylation. A reduction in STAT3 phosphorylation at both Y705 and S727 residues was observed in six out of seven patient samples, while total STAT3 levels remained unchanged. Signal Transduct Target Ther. 2017 Oct 27;2:17051

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Chick embryos CAM assay Topical application 50 μM 24 hours Reduced new vessel formation Int J Biol Sci. 2011;7(5):629-44
C57BL/6 mice Hepatocellular carcinoma model in a fibrotic/cirrhotic liver setting Tail vein injection 35 mg/kg Every other day for 2 weeks LipC6 injection slowed tumor growth, reduced the number and immunosuppressive function of tumor-associated macrophages (TAMs), and promoted TAM differentiation into an M1 phenotype, thereby enhancing the antitumor activity of CD8+ T cells. Gastroenterology. 2018 Mar;154(4):1024-1036. e9

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.51mL

0.50mL

0.25mL

12.57mL

2.51mL

1.26mL

25.15mL

5.03mL

2.51mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories